News | April 27, 2024
AstraZeneca 1Q 2024 revenue up 19% to US$ 12,679 million
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
Additional data in pregnant adults who are Virologically suppressed reinforce safety and tolerability profile of Biktarvy in broad range of people with HIV
The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios
One form of thalidomide has the intended sedative effect but the opposite mirror-image form interferes with foetal development
Open a printable version of this pageEmail the URL of this page to a friend
Approval from Colombia's INVIMA will accelerate growth in Colombia, by registering our product and getting regular supplies
Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program
Breakthrough Therapy designation for pain associated with DPN granted by FDA
10th edition of the event is scheduled to be held during May 30-June 1 at Hitex, Hyderabad
Submission based on results from pivotal phase III trial showing all primary endpoints met
Subscribe To Our Newsletter & Stay Updated
